Britain’s medicines regulator said on Thursday it had approved the use of Moderna Inc’s COVID-19 vaccine in children between six and 11 years, as the country bolsters itself for fighting coronavirus infections.
The Medicines and Healthcare products Regulatory Agency (MHRA) said the approval was granted after Moderna's vaccine, known as Spikevax, met the required standards of safety, quality and effectiveness.
For the latest headlines, follow our Google News channel online or via the app.
Spikevax was already approved in Britain for those over 12 years, and the extension to include younger children comes hours after the regulator approved French firm Valneva's easy-to-store COVID-19 vaccine for adults up to 50 years of age.
MHRA chief June Raine said in a statement it would be up to Britain’s Joint Committee on Vaccination and Immunization to advise on whether Moderna’s vaccine will be offered to the younger group as part of the country’s immunization program.
Read more:
New COVID-19 vaccine may also protect cancer patients with weak immunity: Study
Pfizer to expand COVID-19 booster shots to healthy five to 11-year-olds in US
Worldwide COVID-19 cases surpass 500 million as omicron variant BA.2 surges
